Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis

Exclusion Criteria

• •1. Known history of hypogammaglobulinemia, immotile cilia syndrome, atrophic rhinitis, rhinitis medicamentosa, or cystic fibrosis
• •2. Known hypersensitivity to Cyclamen, Primula, or other Primulaceae
• •3. Serious unstable comorbidity such as malignancy (other than squamous or basal cell carcinoma of the skin) or sever renal or hepatic disease.
• •4. Abnormal screening laboratory/imaging test results
• •5. Condition(s) that compromise the ability to either administer the agent or assess the risks/benefits (eg mucocele, choanal polyp, Stage 4 polyposis or cyst extending below the inferior turbinate, deviated septum, facial trauma, or birth defect)
• •6. Expansile mass or bony erosion on sinus radiograph
• •7. Females who are pregnant, planning to become pregnant or currently breastfeeding.
• •8. History of viral upper respiratory infection (URI) in the past 2 weeks
• •9. Temperature greater than 102.5°F
• •10. Facial or periorbital edema
• •11. Local complications including orbital cellulitis; acute abnormalities of extraocular movements; cavernous vein thrombosis; dental or facial abscess
• •12. Altered mental status
• •13. Recent nasal or sinus surgery (within 3 months or less) or planned surgery within the next 3 months
• •14. Use of intranasal antibiotics within the previous 30 days or systemic antibiotics within the previous 15 days
• •15. Use of oral and/or topical nasal decongestants within the previous 7 days
• •16. Had radiation therapy or chemotherapy within the previous 12 months
• •17. Have used an investigational drug or device within 30 days prior to screening
• •18. Have a history of illegal drug or alcohol abuse within the past 5 years
• •19. Have major unstable organ system disease that could place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives Subjects who have asthma, seasonal and/or perennial allergic rhinitis will be allowed to enter the study.